Whalesbook
Toh hua kya hai ki shareholders ne approved kiya hai ki company 1.6 million equity shares buyback karegi ₹40 crore mein, aur price rakha hai ₹250 per share. Yeh price last day ke closing price ₹178.90 se 39.74% zyada hai. Aur bhi interesting baat yeh hai ki yeh ₹250 wala buyback price, stock ke current trading price ₹203.48 se bhi kaafi upar hai. Iska matlab jo shareholders buyback mein participate karenge unhe fayda ho sakta hai, par yeh ek bada valuation disconnect bhi dikhata hai. Waise, Jagsonpal ka stock pichhle ek saal mein 17.34% gir chuka hai. Iska 52-week range ₹155.00 se ₹301.65 raha hai, jo recent underperformance show karta hai. Announcement wale din stock 2.15% bada, but Nifty Pharma index jo 2.56% bada, uske comparison mein thoda peeche reh gaya.
Ab valuation ki baat karein toh Jagsonpal Pharma ka market cap lagbhag ₹1,337.4 crore hai. Indian pharma sector mein yeh ek chhoti company hai. Iska TTM Price-to-Earnings (P/E) ratio 32.75x hai, jo industry average P/E 29.2x aur iske peers ke average 22.8x se zyada hai. Matlab, competitors ke comparison mein Jagsonpal ka valuation thoda high lag raha hai, aur iske competitors mein Sun Pharma jaise bade players hain jinka market cap ₹414,713 Cr aur ₹96,602 Cr hai. Company ka sales growth bhi pichhle 5 saal mein 11.1% hi raha hai, jo moderate hai.
Sabse badi chinta yeh hai ki buyback price aur current trading price mein itna bada gap hai, valuation bhi high lag raha hai, aur future outlook bhi clear nahi. Jagsonpal Pharma ko koi analyst cover nahi karta; matlab koi revenue ya earnings estimate nahi hai. Kuch forecasts toh bohot bearish hain, ek projection toh yeh bhi keh raha hai ki stock April 2031 tak ₹17.12 tak gir sakta hai! Analyst support ki kami aur valuation ka high hona yeh batata hai ki capital ka use shayad efficient nahi ho raha. Estimate hai ki iski intrinsic value current market price se 33% kam hai, yani yeh overvalued ho sakta hai. Buyback ke baad promoters ki stake badhegi kyunki woh participate nahi karenge, par yeh fundamental valuation issues ko solve karega, yeh kehna mushkil hai.
Company ka kehna hai ki buyback se capital structure optimize hoga, EPS improve hoga aur long-term shareholder value badhegi. Management kehti hai ki shareholders ka approval unki strategy aur financial discipline par bharosa dikhata hai. Par sach toh yeh hai ki Indian pharma sector bohot tezi se badal raha hai, innovation aur R&D par focus badh raha hai. Toh buyback se capital management ka issue solve ho sakta hai, but long-term growth ke liye company ko competitive rehna aur innovate karna hoga, yeh dekhna important hoga.